avibactam (Avycaz) Report issue

Small molecule Approved FDA Fast Track FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Avibactam (formerly NXL104, AVE1330A) is a synthetic non-β-lactam, covalent, slowly reversible β-lactamase inhibitor that inhibits the activities of Ambler class A and C β-lactamases and some Ambler class D enzymes. The combination of ceftazidime with avibactam exhibited broad-spectrum activity against Ambler class A- and class C-producing Enterobacteriaceae. AVYCAZ is a combination of ceftazidime, a cephalosporin, and avibactam indicated for the treatment of patients with the following infections caused by designated susceptible microorganisms: Complicated Intra-abdominal Infections, used in combination with metronidazole and Complicated Urinary Tract Infections, including Pyelonephritis.   NCATS

Chemistry

  • SMILES: NC(=O)[C@@H]1CC[C@@H]2CN1C(=O)N2OS(=O)(=O)O
  • InChIKey: NDCUAPJVLWFHHB-UHNVWZDZSA-N
  • Mol. Mass: 265.25
  • ALogP: -1.53
  • ChEMBL Molecules:
    avibactam  
    avibactam sodium  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Combination drugs

( avibactam (Avycaz), ceftazidime (fortaz) - other names: avibactam and ceftazidime, zavicefta, ceftazidime-avibactam )

Alternative names

ave1330a | avibactam | avibactam - ceftazidime | avibactam, ceftazidime drug combination | avibactam sodium | avycaz | ceftazidime / avibactam | ceftazidime-avibactam | nxl104 | nxl 104 | nxl-104

Organizations (31)

Research & Development (30)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (3)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (21)

Approved Indications (3)


 

Intraabdominal Infections

Pyelonephritis

Urinary Tract Infections

Experimental Indications - Clinical Trial Phases 1-4 (21)


 

Bacteremia (Phase 4)

Bacterial Infections (Phase 3)

Corneal Diseases (Phase 3)

Cystic Fibrosis (Phase 4)

Drugs, Investigational (Phase 1)

Febrile Neutropenia (Phase 2)

Gram-Negative Bacterial Infections (Phase 2)

Healthcare-Associated Pneumonia (Phase 4)

Healthy Volunteers (Phase 1)

Infections (Phase 2)

Inflammation (Phase 1)

Intestinal Neoplasms (Phase 1)

Intraabdominal Infections (Phase 4)

Kidney Diseases (Phase 1)

Neoplasms (Phase 2)

Pharmacokinetics (Phase 1)

Pneumonia, Ventilator-Associated (Phase 4)

Pyelonephritis (Phase 4)

Renal Insufficiency (Phase 1)

Safety (Phase 1)

Urinary Tract Infections (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 42
  • # of Trial Organizations: 30

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue